Anaheim Bio launches with €40M to tackle untreated joint disease
What's the deal? Anaheim BioDealroom has a profile for this one. Try Dealroom →, a preclinical biotech based in Leiden, Netherlands, has raised €40 million in an oversubscribed Series A to develop ANA-1, a drug for calcium pyrophosphate deposition disease (CPPD). Droia Ventures led the round, joined by Frazier Life SciencesDealroom has a profile for this one. Try Dealroom →, RTW, Novartis Venture FundDealroom has a profile for this one. Try Dealroom →, RV InvestDealroom has a profile for this one. Try Dealroom →, and Thuja CapitalDealroom has a profile for this one. Try Dealroom →.
What's the endgame? ANA-1 is a small-molecule inhibitor designed to lower extracellular pyrophosphate, the raw material for the calcium crystals that drive CPPD. The company says the financing funds IND-enabling studies and a first-in-human trial expected in 2027, with runway into 2028.
Why it matters: CPPD, a form of inflammatory arthritis, affects an estimated 4% to 7% of adults in Europe and the US, yet no approved drug removes the underlying crystal deposits. Current treatments only manage inflammation and symptoms during flares.
"ANA-1 is designed to directly address the underlying pathology of CPPD and has the potential to change treatment for the millions of people worldwide who today have no therapy that targets the crystal deposits driving the disease," said chief executive officer Ilan Ganot.
The backstory: Anaheim is a spinout of Alesta Therapeutics, formed from programs carved out before BioMarin acquired Alesta in August 2026 for $275 million upfront plus up to $215 million in milestones. All six Series A investors previously backed Alesta. Ganot, Alesta's former CEO, leads the new company, with Droia's Luc Dochez as board chair.
What could go wrong? ANA-1 remains untested in humans, and lowering pyrophosphate carries a known trade-off: the molecule also restrains unwanted mineralization in healthy tissue, such as blood vessels. Whether the drug can cut crystal formation in joints without disrupting those roles is unresolved, and the older CPPD population raises added safety concerns.
The signal: The round shows investor and pharma appetite for the pyrophosphate pathway, the same target behind BioMarin's acquisition. For Anaheim, backing from Alesta's legacy investors is a vote of confidence—but ANA-1's promise rests on clinical data it has yet to produce.
Read more: webdisclosure.com
Image credit: Generated with Gemini
